

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Chariag Belgacem</u>	2. Date of Event Requiring Statement (Month/Day/Year) 07/03/2017	3. Issuer Name and Ticker or Trading Symbol <u>Baker Hughes a GE Co [BHGE]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Global Ops Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
(Last) (First) (Middle) <u>17021 ALDINE WESTFIELD ROAD</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
(Street) <u>HOUSTON TX 77073</u>			
(City) (State) (Zip)			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Class A Common Stock</u>	<u>192,902.7745</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>01/19/2020</u>	<u>Class A Common Stock</u>	<u>12,000</u>	<u>29.78</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>07/21/2020</u>	<u>Class A Common Stock</u>	<u>11,600</u>	<u>31.67</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>01/26/2021</u>	<u>Class A Common Stock</u>	<u>9,300</u>	<u>44.82</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>07/19/2021</u>	<u>Class A Common Stock</u>	<u>7,500</u>	<u>59.5</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>01/25/2022</u>	<u>Class A Common Stock</u>	<u>22,619</u>	<u>29.94</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>07/16/2022</u>	<u>Class A Common Stock</u>	<u>18,208</u>	<u>21.8</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>01/24/2023</u>	<u>Class A Common Stock</u>	<u>25,875</u>	<u>27.71</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>07/24/2023</u>	<u>Class A Common Stock</u>	<u>24,508</u>	<u>30.25</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>01/22/2024</u>	<u>Class A Common Stock</u>	<u>23,914</u>	<u>39.23</u>	<u>D</u>	
<u>Stock Option (Right to Buy)</u>	<u>07/03/2017</u>	<u>07/14/2024</u>	<u>Class A Common Stock</u>	<u>18,670</u>	<u>55.2</u>	<u>D</u>	
<u>Restricted Stock Unit 1_17A</u>	<u>(1)</u>	<u>(1)</u>	<u>Class A Common Stock</u>	<u>26,138</u>	<u>(1)</u>	<u>D</u>	
<u>Restricted Stock Unit 1_17B</u>	<u>(2)</u>	<u>(2)</u>	<u>Class A Common Stock</u>	<u>26,138</u>	<u>(2)</u>	<u>D</u>	

Explanation of Responses:

- These Issuer RSUs (and the associated right with respect to the special one-time cash dividend of \$17.50 per share of Issuer Common Stock (the "Special Dividend")) are scheduled to vest in three equal installments beginning January 25, 2018.
- These Issuer RSUs (including the right with respect to the Special Dividend) are scheduled to vest based solely on service on January 25, 2020.

Remarks:

Following the consummation of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 30, 2016, among General Electric Company, a New York corporation, Baker Hughes Incorporated, a Delaware corporation ("BHI"), the Issuer and certain subsidiaries of BHI, as amended by that certain Amendment to Transaction Agreement and Plan of Merger dated as of March 27, 2017 (the "Transaction Agreement"), the Reporting Person became an Officer of the Issuer. Exhibit 24 - Power of Attorney

/s/ Lee Whitley, Attorney-in-fact 07/03/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EXECUTIVE OFFICER'S QUESTIONNAIRE – BAKER HUGHES, A GE COMPANY
(Provide responses on additional sheets if needed.)

SECTION 16 CERTIFICATION

14. Limited Power of Attorney for Section 16 Reporting Obligations.

I, Belgacem Chariag, hereby appoint Baker Hughes, a GE Company, to assist me in the preparation and filing of Section 16 reports, and execute the below Power of Attorney for this purpose.

I am an executive nominee for Baker Hughes, a GE Company, and until further written notice, I hereby individually authorize Lee Whitley (Corporate Secretary), William Marsh (General Counsel) and any assistant secretary of Baker Hughes, a GE Company, to sign on my behalf any Form 3, Form 4, Form 5, Form 144 or related form that I have filed or may file hereafter in connection with my direct or indirect beneficial ownership of securities of Baker Hughes, a GE Company, and to take any other action of any type whatsoever in connection with the foregoing that in her or his opinion may be for the benefit of, in the best interest of, or legally required by me.

06-07-2017
Date

Signed: 
Belgacem Chariag

